| Name | Title | Contact Details |
|---|
The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.
Amylyx is a Cambridge-based pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders. Guided by our core values, we incorporate unconventional approaches through strong partnerships with industry leaders, scientists, doctors and organizations. We work collaboratively across everything we do to positively impact the lives of patients and their families.
Industrial Pharmaceutical Resources, Inc. is a Bartlett, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient`s dendritic cells to activate an immune response specific to the patient`s disease. Argos` most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. Argos Therapeutics is headquartered in Research Triangle Park, NC. The Company has clinical stage programs in Phase 3 (metastatic renal cell carcinoma), Phase 2b (HIV) and Phase 1a (systemic lupus erythematosus1) development.
Collagen Matrix advances the science of tissue repair and regeneration with collagen and mineral based medical devices that support the bodys natural ability to regenerate.